Clinical Trials
2 trialsNCT03739814 2026-06-03
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT01838642 2017-02-15
Ponatinib for Advanced Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated